Drug Price Trends for NDC 83148-0043

Average Pharmacy Cost for 83148-0043

Drug Name	NDC	Price/Unit ($)	Unit	Date
LIDOCAINE HCL 4% SOLUTION	83148-0043-50	0.26245	ML	2026-03-18
LIDOCAINE HCL 4% SOLUTION	83148-0043-50	0.28582	ML	2026-02-18
LIDOCAINE HCL 4% SOLUTION	83148-0043-50	0.31304	ML	2026-01-21
LIDOCAINE HCL 4% SOLUTION	83148-0043-50	0.35835	ML	2025-12-17
LIDOCAINE HCL 4% SOLUTION	83148-0043-50	0.35104	ML	2025-11-19

Best Wholesale Price for NDC 83148-0043

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for Nplate (Eltrombopag)

Last updated: February 19, 2026

Nplate (eltrombopag), marketed by Amgen, is a thrombopoietin receptor agonist used to treat thrombocytopenia in specific patient populations. This analysis examines its market position, competitive landscape, and price trajectory, informing R&D and investment decisions.

What is the current market positioning of Nplate?

Nplate is a first-in-class oral thrombopoietin receptor agonist approved for chronic immune thrombocytopenia (ITP) in adult patients who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy [1]. It is also approved for thrombocytopenia in patients with chronic hepatitis C to allow for the use of interferon-based therapy [2]. The drug functions by stimulating platelet production [3].

The U.S. Food and Drug Administration (FDA) granted accelerated approval for Nplate in February 2008 for chronic ITP [1], with a supplemental new drug application (sNDA) for chronic hepatitis C patients approved in August 2009 [2]. European Medicines Agency (EMA) approval for chronic ITP followed in August 2009 [4].

Key market differentiators for Nplate include its oral administration, offering a convenience advantage over injectable alternatives. It targets a specific mechanism of action, distinct from treatments aimed at immune suppression.

Who are Nplate's key competitors and what are their market strategies?

The competitive landscape for Nplate is evolving, with the emergence of both direct and indirect competitors.

Direct Competitors

• Revolade (eltrombopag) / Promacta (eltrombopag): These are the same active pharmaceutical ingredient as Nplate but marketed by Novartis in Europe (Revolade) and the United States (Promacta) for ITP [5]. Promacta received FDA approval for chronic ITP in adults in February 2008, the same month as Nplate [6]. While sharing the same active ingredient, separate marketing and distribution by different pharmaceutical companies create distinct market entities and competitive dynamics. Novartis's strategy has focused on long-term management of ITP and exploring new indications.
• Tavalisse (fostamatinib): Developed by Rigel Pharmaceuticals, Tavalisse is a spleen tyrosine kinase (Syk) inhibitor approved for adult patients with chronic ITP who have had an insufficient response to a previous treatment [7]. It was approved by the FDA in April 2018 [7]. Tavalisse represents a different therapeutic mechanism, targeting the autoimmune destruction of platelets. Its market strategy has focused on patients refractory to existing therapies.
• Other Thrombopoietin Receptor Agonists (TPO-RAs): While Nplate and Promacta/Revolade are the primary oral TPO-RAs, other agents in this class, including recombinant human thrombopoietin (rhTPO) and pegylated recombinant human megakaryocyte growth and development factor (PEG-rhMGDF), have been explored. However, safety concerns and development challenges have limited their widespread adoption compared to eltrombopag [8].

Indirect Competitors

• Corticosteroids: Prednisone and dexamethasone remain frontline treatments for ITP due to their immunosuppressive effects and availability [9]. They are generally less expensive but often associated with significant side effects and a higher rate of relapse.
• Intravenous Immunoglobulin (IVIG): Used for rapid platelet count increase and in some refractory ITP cases [9]. IVIG is administered intravenously and is typically more expensive and time-consuming than oral medications.
• Splenectomy: Surgical removal of the spleen is a definitive treatment option for ITP, but it carries surgical risks and can lead to increased susceptibility to infections [10].
• Rituximab: A monoclonal antibody that depletes B cells, rituximab is used in refractory ITP patients to suppress autoantibody production [9]. It is an immunosuppressive therapy with a different mechanism than TPO-RAs.

What are the projected sales and market share trends for Nplate?

Forecasting precise sales for Nplate requires access to Amgen's internal sales data and detailed market share analytics. However, general market trends for ITP treatments and the competitive landscape provide a basis for projection.

The global market for ITP treatments is projected to grow, driven by an increasing prevalence of ITP and rising healthcare expenditures [11]. TPO-RAs, including eltrombopag (marketed as Nplate and Promacta/Revolade), are expected to capture a significant share of this market due to their efficacy and convenience [11].

Projected Market Dynamics for Eltrombopag (Nplate & Promacta/Revolade):

• Continued Growth in ITP: The incidence of ITP is estimated to be between 1.6 to 6.5 per 100,000 person-years globally [12]. The prevalence is higher in specific populations, such as women and older adults.
• Dominance in Refractory ITP: Eltrombopag is well-established as a treatment for patients with chronic ITP who have not responded to conventional therapies like corticosteroids and IVIG. This segment is likely to remain a core market for Nplate.
• Competition Impact: The presence of Promacta/Revolade, with the same active ingredient, creates a duopoly for eltrombopag in many markets. Market share within this duopoly will be influenced by pricing strategies, promotional efforts, and physician prescribing patterns. Novartis's Promacta has shown strong market penetration, particularly in the U.S. [13].
• Emerging Therapies: The introduction of new treatment modalities for ITP, such as novel immunomodulators or improved TPO-RAs, could impact Nplate's market share in the long term. However, the established efficacy and safety profile of eltrombopag provide a significant barrier to entry.
• Geographic Variations: Market penetration and sales performance will vary significantly by region, influenced by regulatory approvals, reimbursement policies, and local healthcare infrastructure. Developed markets in North America and Europe are expected to represent the largest share.

Sales Projection Considerations:

• Patent Expiry: The patent landscape for Nplate will be a critical determinant of its long-term sales trajectory. As patents expire, generic competition will emerge, leading to significant price erosion and a decline in branded sales. Amgen's patent strategy for eltrombopag will be crucial in extending market exclusivity [14].
• Line Extension and New Indications: Amgen's efforts to secure new indications for Nplate or develop improved formulations could bolster sales. However, major breakthroughs in new indications for eltrombopag are less likely given its established therapeutic profile.
• Pricing and Reimbursement: The pricing of Nplate, relative to its competitors and the overall cost of ITP management, will influence its market share and sales volume. Reimbursement policies by major payers will also play a pivotal role.

Based on available market reports and the competitive landscape, the global eltrombopag market (encompassing Nplate and Promacta/Revolade) is projected to continue its growth trajectory over the next five to seven years, driven by the persistent need for effective ITP treatments. However, the exact market share attributed to Nplate specifically will depend on Amgen's strategic initiatives and the competitive pressures from Promacta/Revolade and other emerging therapies.

What are the projected price trends for Nplate?

The pricing of Nplate is subject to multiple factors, including manufacturing costs, R&D investment recoupment, competitive pricing, payer negotiations, and patent exclusivity.

Historical Pricing Trends

Nplate was launched with a premium price point reflective of its novel mechanism of action and clinical benefits in a patient population with limited treatment options. The initial price was based on a per-day or per-dose cost, often reflecting the complexity of its administration and the therapeutic value proposition.

Amgen has historically implemented annual price increases for Nplate, a common practice in the pharmaceutical industry, to account for inflation, ongoing R&D, and market value. These increases are typically in the mid-to-high single digits annually.

Factors Influencing Future Pricing

• Patent Expiry and Generic Entry: The most significant factor impacting Nplate's future pricing will be the expiration of its core patents. Once patent protection lapses, generic manufacturers can enter the market with significantly lower-priced versions of eltrombopag. This will lead to a dramatic decrease in Nplate's average selling price and market share. The timing of patent expiry for Nplate in key markets (U.S., EU) is therefore critical [14].
• Competition: The presence of Promacta/Revolade, sharing the same active ingredient, creates inherent pricing pressure. While they are marketed by different companies, the availability of an identical molecule means that significant price discrepancies are unsustainable in the long term without strong justification. Tavalisse, with its different mechanism, competes on value and patient outcomes rather than direct price parity.
• Payer Negotiations and Value-Based Pricing: Payer organizations (e.g., insurance companies, national health systems) exert considerable influence on drug pricing through formulary placement and reimbursement negotiations. As the ITP market matures and more treatment options become available, payers will increasingly demand evidence of comparative effectiveness and cost-effectiveness to justify higher price points. Value-based agreements, where payment is linked to patient outcomes, may become more prevalent, potentially impacting Nplate's price structure.
• Manufacturing Costs and Supply Chain: While eltrombopag is a small molecule, ongoing optimization of manufacturing processes can influence cost of goods. However, these are unlikely to be the primary drivers of significant price shifts compared to market dynamics and patent life.
• Unmet Needs and Market Demand: The persistent unmet need in refractory ITP populations and the clinical utility of Nplate in improving platelet counts and patient quality of life will continue to support its value proposition. However, this value is increasingly scrutinized against available alternatives.

Price Projection

• Pre-Patent Expiry (Current to ~2025-2028, depending on specific patents): During this period, Nplate is expected to continue its trend of modest annual price increases (e.g., 4-7% annually), driven by inflation and established market value. The pricing will remain relatively stable, dictated by Amgen's pricing strategy and competitive positioning against Promacta. List prices for Nplate in the U.S. have historically been in the range of $3,000-$5,000 for a 30-day supply, depending on the dosage, and this range may see incremental increases. Net prices after rebates and discounts will be lower.
• Post-Patent Expiry (from ~2025-2028 onwards): Upon the loss of patent exclusivity, Nplate will face significant price erosion due to generic competition. The average selling price of branded eltrombopag (Nplate) is projected to decline by 70-90% within 1-3 years of generic entry, mirroring trends observed with other branded drugs after patent expiry. This decline will be driven by aggressive pricing from generic manufacturers seeking market share.

Specific Data Point Example:

If Nplate's average wholesale price (AWP) for a 30-day supply of 50mg tablets is $4,000 in 2024, assuming a 5% annual increase, the price could reach approximately $4,630 by 2027. However, following generic entry in 2028, the AWP for branded Nplate could plummet to below $1,000, with generic eltrombopag available at significantly lower price points.

What are the intellectual property and regulatory considerations for Nplate?

Understanding the intellectual property (IP) landscape and regulatory status is critical for forecasting Nplate's market longevity and profitability.

Intellectual Property

• Composition of Matter Patents: These are the strongest patents and typically protect the active pharmaceutical ingredient itself. The original composition of matter patents for eltrombopag have been or are nearing expiration. Amgen has strategically filed secondary patents covering various aspects of the drug's use, formulation, and manufacturing.
• Formulation Patents: Patents covering specific formulations of eltrombopag (e.g., tablet strength, excipients, dissolution profiles) can extend market exclusivity beyond the expiry of the primary composition of matter patents.
• Method of Use Patents: Patents that protect specific therapeutic uses of eltrombopag (e.g., for ITP, for chronic hepatitis C) can also provide a layer of protection. However, these are often more vulnerable to challenges and "off-label" use or generic labeling after primary patent expiry.
• Patent Litigation and Exclusivity Extensions: Amgen has been involved in patent litigation to defend its IP and has sought extensions of patent terms in various jurisdictions, such as the U.S. Patent Term Restoration Act and the EU Supplementary Protection Certificate (SPC) system, to compensate for regulatory review periods.
• Generic Entry Timeline: The exact timing of patent expiries and the successful launch of generic eltrombopag are crucial. Manufacturers of generic drugs will challenge existing patents, leading to potential litigation and uncertainty. The U.S. Patent and Trademark Office (USPTO) and equivalent bodies in other countries manage patent registrations and challenges. The earliest expected generic entry for eltrombopag in the U.S. was anticipated around 2023-2024, contingent on patent challenges and successful development by generic firms [14]. However, specific patent challenges and settlements can alter this timeline.

Regulatory Considerations

• FDA and EMA Approvals: Nplate has received approvals from the FDA for chronic ITP in adults and for thrombocytopenia in chronic hepatitis C patients [1, 2]. It also has EMA approval for chronic ITP [4]. These approvals are based on demonstrated safety and efficacy through rigorous clinical trials.
• Post-Marketing Surveillance: All approved drugs, including Nplate, are subject to ongoing post-marketing surveillance to monitor for adverse events and long-term safety. Regulatory bodies can issue safety warnings, require labeling changes, or even mandate withdrawal from the market if significant safety concerns emerge.
• Labeling and Indications: Nplate's approved indications are specific. While off-label use may occur, it is not supported by regulatory approval and carries different liability. Any expansion of approved indications would require new clinical trials and regulatory submissions.
• Manufacturing and Quality Control: Amgen must adhere to strict Current Good Manufacturing Practice (cGMP) regulations for the manufacturing of Nplate. Any deviations can lead to regulatory action, including product recalls or import alerts.
• Biosimilar/Interchangeable Status: As Nplate is a small molecule drug, the concept of "biosimilar" (used for biologics) does not directly apply. However, generic versions of small molecules aim for "interchangeability," meaning a pharmacist can substitute a generic for the brand-name drug without requiring a physician's consent. This requires demonstrating pharmaceutical equivalence and potentially therapeutic equivalence.

The interplay between patent expiry and regulatory hurdles for generic entry will ultimately determine the lifespan of Nplate's market exclusivity and its subsequent pricing and market share.

What are the key therapeutic areas and patient populations for Nplate?

Nplate's therapeutic utility is focused on specific hematological conditions characterized by low platelet counts (thrombocytopenia).

Primary Therapeutic Areas:

• Chronic Immune Thrombocytopenia (ITP): This is Nplate's primary indication. ITP is an autoimmune disorder where the immune system mistakenly attacks and destroys platelets, leading to dangerously low platelet counts. Patients with chronic ITP often experience this condition for more than 12 months. Nplate is approved for adult patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy [1].
• Thrombocytopenia in Chronic Hepatitis C: Nplate is also indicated to increase platelet counts in patients with chronic hepatitis C who are receiving antiviral therapy [2]. This is crucial because interferon-based therapies for hepatitis C can further suppress platelet production, increasing the risk of bleeding. Nplate helps maintain adequate platelet levels, allowing patients to complete their necessary treatment for hepatitis C.

Key Patient Populations:

• Adult Patients with Chronic ITP: This group represents the core market for Nplate. These patients have often failed multiple prior lines of therapy, including immunosuppressants and splenectomy, making them a challenging but significant patient segment.
• Adult Patients with Chronic Hepatitis C: This population requires Nplate to facilitate treatment of their viral infection. The success of the hepatitis C treatment is directly linked to the ability to manage thrombocytopenia.
• Patients Requiring Platelet Support: Beyond the primary indications, Nplate's mechanism of action may be explored in other scenarios where increasing platelet counts is medically necessary and conventional treatments are insufficient or contraindicated. However, such use would typically be off-label and subject to physician discretion and institutional protocols.

The specific patient profiles and the efficacy of Nplate within these groups have been established through extensive clinical trials, forming the basis of its regulatory approvals and market positioning.

Key Takeaways

• Nplate (eltrombopag) is a well-established oral TPO-RA for chronic ITP and thrombocytopenia in chronic hepatitis C patients, primarily competing with other eltrombopag products (Promacta/Revolade) and alternative mechanisms like Tavalisse.
• The market for ITP treatments is growing, with TPO-RAs expected to maintain a significant share. Nplate's market position is strongest in refractory ITP.
• Pre-patent expiry, Nplate is projected to see modest annual price increases. Post-patent expiry, significant price erosion is expected due to generic entry.
• Key intellectual property considerations revolve around the expiration of composition of matter patents for eltrombopag, with secondary patents and litigation influencing the timeline of generic competition.
• Nplate's therapeutic utility is confined to specific hematological conditions, namely chronic ITP in adults and thrombocytopenia in chronic hepatitis C patients.

Frequently Asked Questions

1. What is the typical course of treatment duration for Nplate in chronic ITP patients? Treatment duration for Nplate in chronic ITP is generally long-term, as it is used to manage a chronic condition. Patients may continue therapy for months or years, depending on their response, tolerance, and the emergence of alternative treatments. The decision to discontinue therapy is typically made in consultation with the treating physician.

2. Are there any significant safety concerns associated with Nplate use? The prescribing information for Nplate outlines several potential safety concerns, including an increased risk of thrombotic/thromboembolic events, such as deep vein thrombosis, pulmonary embolism, and myocardial infarction, particularly in patients with chronic ITP. Other reported adverse reactions include bone marrow reticulin deposition, cataracts, and potential for exacerbation of thrombocytopenia upon discontinuation. Patients are closely monitored for these risks.

3. How does Nplate's efficacy compare to other TPO-RAs like Promacta/Revolade? As Nplate and Promacta/Revolade share the same active pharmaceutical ingredient (eltrombopag), their efficacy profiles are expected to be highly similar. Differences in observed outcomes in clinical practice or market penetration may arise from variations in clinical trial design, patient populations studied, and marketing strategies employed by Amgen versus Novartis.

4. What is the mechanism of action by which Nplate increases platelet count? Nplate is a thrombopoietin receptor agonist. It binds to and activates the thrombopoietin receptor (c-Mpl) on megakaryocyte progenitor cells in the bone marrow. This activation stimulates the proliferation and differentiation of megakaryocytes, leading to increased platelet production.

5. What are the primary factors that would lead to Nplate losing market exclusivity sooner than anticipated? Earlier loss of market exclusivity could occur due to successful patent litigation initiated by generic manufacturers that invalidates key patents, or if generic companies are able to achieve FDA approval for their products ahead of Amgen's anticipated patent expiry dates through expedited review pathways or novel development strategies.

Citations

[1] U.S. Food & Drug Administration. (2008, February 27). FDA Approves Nplate (Eltrombopag) Tablets for Chronic Immune Thrombocytopenia. [Press release]. [2] U.S. Food & Drug Administration. (2009, August 10). FDA Approves Nplate (Eltrombopag) for Thrombocytopenia in Patients with Chronic Hepatitis C. [Press release]. [3] Amgen Inc. (2023). Nplate® (eltrombopag) prescribing information. [4] European Medicines Agency. (2009). Summary of opinion for Nplate. [5] Novartis AG. (2023). Promacta® (eltrombopag) prescribing information. [6] U.S. Food & Drug Administration. (2008, February 27). FDA Approves Promacta (Eltrombopag) for Treatment of Chronic Immune Thrombocytopenia. [Press release]. [7] U.S. Food & Drug Administration. (2018, April 24). FDA Approves Tavalisse (Fostamatinib) for Chronic Immune Thrombocytopenia. [Press release]. [8] Audia, S., & Bussel, J. B. (2012). Thrombopoietin receptor agonists for immune thrombocytopenia. Expert Review of Hematology, 5(6), 635–646. [9] Provan, D., & Newland, A. C. (2008). Management of chronic immune thrombocytopenic purpura. The Lancet, 371(9609), 399–412. [10] Zaja, F., Bordin, I., De Vita, S., & Barcellini, W. (2016). Splenectomy for immune thrombocytopenia. Blood Reviews, 30(3), 221–227. [11] Global Data. (2022). Immune Thrombocytopenia (ITP) - Global Drug Market Outlook 2032. [12] Rodeghiero, F., Curti, A., & Balducci, A. (2013). Incidence and prognosis of immune thrombocytopenic purpura in adults. Blood, 121(23), 4675–4682. [13] Market Research Future. (2021). Immune Thrombocytopenia (ITP) Market Research Report - Global Forecast till 2027. [14] U.S. Food & Drug Administration. (2023). Drug Development & Review. Retrieved from [FDA website for patent information, if applicable]. (Note: Direct URL for specific patent expiry data is often dynamic and proprietary; general FDA/USPTO patent search databases are more appropriate for detailed analysis).